Lupin Limited announced the achievement of key milestones for Lupins MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers.
As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim
for achievement of key milestones.
Lupin and Boehringer Ingelheim inked a licensing, development and commercialization agreement
in 2019 for Lupin’s novel oncology compound to treat KRAS-driven cancers. Lupin’s MEK inhibitor
developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent
as well as in combination.
Lupin’s New Chemical Entity Research team is focused on building a pipeline of highly differentiated
and innovative new chemical entities, primarily in the oncology space. Lupin’s NCE activities were
started with the vision to use cutting-edge research in bringing novel molecules that address unmet
medical needs in multiple therapeutic areas to market globally.
